Orano Med is a nuclear biotech company developing innovative therapies in oncology. It has developed new processes for producing lead-212 (²¹²Pb), a rare radioactive isotope used in Targeted Alpha Therapy (TAT), an innovative and promising approach of nuclear medicine allowing to recognize and destroy cancer cells while limiting the impact on nearby healthy cells.

Orano Med

Based on an R&D program started in 2005, Orano Med has developed new processes for producing high-purity lead-212 (Pb-212), a rare radioactive isotope.  Lead-212 is currently at the heart of promising projects in nuclear medicine to develop new treatments against cancer.  The innovative approach, known as targeted alpha therapy (TAT), recognizes and destroys cancer cells while limiting the impact on nearby healthy cells. 

Macrocyclics, Inc., an Orano Med company, is the global leader in high performance chelating agent technology, offering a broad range of services and products.  For more information please visit www.macrocyclics.com.

🚀 It is with real enthusiasm that #OranoMed, a subsidiary of the Orano Group specialized in nuclear medicine, today lays foundations for the ATLab in #Onnaing in the #HautsdeFrance region! 🎉 

The ATLab is our first industrial-scale pharmaceutical facility in Europe dedicated to the production of lead-212 based radioligand therapies. This is the culmination of 18 years of research and innovation to meet one of the major challenges of our century: the fight against cancer.

🏗️It also marks the start of a new industrial adventure, with the promise of large-scale production of our treatments as early as 2025. 

Julien Dodet: "We are convinced that radioligand therapies will soon become an essential tool in the fight against cancer. As the Phase II clinical trial of our most advanced drug AlphaMedix nears completion, we are building a global industrial platform to ensure the large-scale production and distribution of these potential treatments."

Guillaume Dureau: "The ATLab in Onnaing is a very important step in our development strategy and is situated at the very heart of the industrial fabric of the Valenciennes metropolitan area and the Hauts-de-France region. The expansion of our production capacity in the radiopharmaceutical field is part of a drive to revitalize our country’s industrial and economic fabric."

🎯 This new step is essential to make targeted alpha therapy for cancer patients a reality. 

Learn more ➡️ https://lnkd.in/eMuvCUFV

#OranoMed #MedicalInnovation #CancerResearch #ATLabValenciennes #FutureOfMedicine #NuclearMedicine #RLT #RadioPharmaceuticals
#Alphatherapy

Laurent Degallaix Lise ALTER Julien Dodet Guillaume Dureau QUENET Guillaume

"Is Pb-212 Really Happening?"
 
📌 Check out this excellent The Journal of Nuclear Medicine - JNM publication from Richard Zimmermann which highlights the growing interest in alpha emitters for radiotherapeutic applications and the industrial credibility of the production of #lead212.
 
📑 "#OranoMed was the first company to believe strongly in the future of Pb-212 and has developed a full production process and started investing in lead-212-labeled drugs. The company is presently building 2 industrial facilities called alphatherapy laboratories (ATLab) in Indianapolis and Valenciennes with a capacity of 10,000-plus doses per year by 2025 and anticipating more than 10 times this number by the end of the decade."

#nuclearmedicine #radiopharmaceuticals #alphaterapy 


📣 [Press release] We are delighted to announce our new collaboration with Molecular Partners!
 
🤝 This partnership aims to advance Radio-DARPin therapies for solid tumors, combining #OranoMed's expertise in lead-212 targeted alphatherapies and #MolecularPartners' leadership in optimizing #DARPins.
Together, based on our different expertise, we can meet three success factors: 

1️⃣ Leveraging a safe, convenient and potent radioactive payload
2️⃣ Achieving effective vectorization
3️⃣ Mastering the intricacies of the supply chain

Orano Med is a clinical-stage biotech company which develops a new generation of targeted therapies against cancer using the unique properties of lead-212, known as Targeted AlphaTherapy. OranoMed is currently conducting a Phase 2 clinical trial of #AlphaMedix in GEP-NET in partnership with Radiomedix, Inc. , and has also recently started a Phase 1 trial with 212Pb-GRPR in patients with solid tumors.

Learn more: https://bit.ly/48yUSts

#nuclearmedicine #RadioDARPins #radiopharmaceuticals #alphatherapy

📢 We are pleased that our CEO, Julien Dodet, our CSO, Julien Torgue, and our Business Development director, Thomas Daniel-Robin, will be in #SanFrancisco for the 42nd J.P. Morgan Healthcare Conference!

Join the #OranoMed team from January 8 to 10 to discuss the development of promising targeted alphatherapies with lead-212 and our next milestones set for 2024!

👉 To find out more about this event, click here: https://lnkd.in/eZBPTdbM 

#jpm2024 #jpmorgan #healthcare #nuclearmedicine #radiopharmaceuticals #alphatherapy  

ORAN

COM:ORANOMED

Orano Med